peptides to heal FAQ

Chronic tendinopathy responds differently because the injury is stuck in a failed healing loop. Ongoing inflammation without progression to proliferation. BPC-157 at higher doses (500 mcg daily for 6–8 weeks) combined with eccentric loading exercises can restart the repair cascade by increasing VEGF expression and breaking the inflammatory stasis. A pilot study in chronic Achilles tendinopathy found that BPC-157 + eccentric heel drops reduced pain and improved function more than eccentric exercises alone, but outcomes were less dramatic than in acute injuries.

Start with GHK-Cu rather than BPC-157 or TB-500. The acute inflammation phase is over, so angiogenic and anti-inflammatory peptides offer diminishing returns. GHK-Cu targets the proliferation and remodeling phases. Still active at week 2–8 post-injury. By improving collagen structure and reducing excessive scar tissue formation. Athletes who begin GHK-Cu during mid-stage healing report better range of motion and lower re-injury rates at 6 months compared to those who used only PT.

Yes, when the peptides target different phases of healing. BPC-157 (angiogenesis) + TB-500 (inflammation control) during weeks 1–4, followed by GHK-Cu (remodeling) during weeks 4–8, addresses the entire repair cascade without redundancy. The key is sequential timing, not simultaneous administration. Stacking BPC-157 and TB-500 together during the acute phase is common in research protocols; adding GHK-Cu during overlapping proliferation/remodeling maximizes tissue quality without extending the protocol unnecessarily.

Bone healing follows different timelines than soft tissue. Fractures require 6–12 weeks for callus formation and remodeling. BPC-157 has documented effects on tendon-to-bone healing and ligament repair, but its role in bone mineralization is less clear. TB-500 supports periosteal stem cell differentiation, which contributes to callus formation. Most orthopedic peptide protocols still use BPC-157 + TB-500 during weeks 1–4 post-surgery, but extend the timeline to 8–10 weeks rather than tapering at week three. GHK-Cu is less relevant for bone repair since its primary mechanism targets collagen remodeling in soft tissue, not mineralized matrix.

Administer BPC-157 no earlier than day 5 post-surgery to avoid interfering with macrophage activity during debris clearance. The inflammatory phase (days 0–5) is necessary. Your body is removing dead cells and preparing the wound bed for new tissue. Introducing angiogenic peptides too early can theoretically prolong swelling by recruiting blood vessels before the site is ready. TB-500 is considered safer for earlier use since its primary mechanism is cell migration rather than vascular recruitment, but most protocols still wait until day 5 to begin any peptide administration. If you've already started during days 0–4, monitor for prolonged swelling or delayed wound closure and consider pausing until inflammation visibly resolves.

Shift protocol focus to GHK-Cu exclusively during weeks 3–8 to optimize remodeling instead. BPC-157 and TB-500 provide minimal benefit after peak fibroblast activity ends around day 21. Their mechanisms target cell recruitment and migration, which are largely complete by week three. GHK-Cu remains effective throughout the remodeling phase because collagen turnover continues for months. You won't recover the accelerated closure rate that earlier peptide use would have provided, but you can still improve final scar quality and tensile strength. Research shows GHK-Cu administered during weeks 4–12 reduces hypertrophic scarring and improves collagen alignment even when started late.